BioPharma Resources

FDA programs

Breakthrough therapy vs fast track: FDA expedited programs compared

Breakthrough therapy vs fast track, accelerated approval and priority review: what each FDA program requires, what it gives, and how often each is used.

By the BioPharma Resources editorial team · Published November 18, 2026 · 6 min read

FDA has four main expedited programs for drugs that treat serious conditions. Fast track and breakthrough therapy are designations that speed up development and review; accelerated approval lets FDA approve a drug based on a surrogate endpoint; and priority review shortens FDA's review goal from 10 months to 6. A single drug can use several at once.

The four programs at a glance

Fast trackBreakthrough therapyAccelerated approvalPriority review
What it isDesignationDesignationApproval pathwayReview designation
In law since1997 (FDAMA)2012 (FDASIA)1992 regulations, written into statute 20121992 (with PDUFA)
Qualifying standardSerious condition and data showing potential to address an unmet medical needSerious condition and preliminary clinical evidence of substantial improvement over available therapy on a clinically significant endpointSerious condition, meaningful advantage over available therapy, and effect on a surrogate or intermediate endpoint reasonably likely to predict clinical benefitWould be a significant improvement in safety or effectiveness for a serious condition
When requestedWith the IND or laterWith the IND or later, ideally by end of phase 2Discussed during development, decided at approvalWith the marketing application
What it givesMore meetings, rolling reviewFast track features plus intensive guidance and senior FDA involvementEarlier approval, with confirmatory trials required6-month review goal instead of 10

FDA's guidance Expedited Programs for Serious Conditions: Drugs and Biologics is the main reference for all four. The rules change through new legislation and guidance, so check FDA's pages for current details.

Fast track

Fast track was created by the Food and Drug Administration Modernization Act of 1997. A drug qualifies if it is intended to treat a serious condition and nonclinical or clinical data show it has the potential to address an unmet medical need. Early in development, animal data or a strong mechanism can be enough.

Its main features, per FDA's fast track page:

  • More frequent meetings and written communication with FDA about the development plan.
  • Eligibility for accelerated approval and priority review if the relevant criteria are met.
  • Rolling review: the sponsor can submit completed sections of its marketing application for review before the whole application is finished.

FDA aims to respond to a fast track request within 60 days. Designation can be withdrawn if the drug no longer meets the criteria.

Breakthrough therapy

Breakthrough therapy designation was created by section 902 of the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA). The bar is higher than fast track: the sponsor needs preliminary clinical evidence, usually from early human trials, that the drug may show substantial improvement over available therapy on one or more clinically significant endpoints.

According to FDA's breakthrough therapy page, designation brings:

  • All fast track features, including rolling review.
  • Intensive guidance on an efficient development program, starting as early as phase 1.
  • Organizational commitment from FDA, including senior managers.

As with fast track, FDA aims to respond to a request within 60 days. FDA can rescind the designation if later data no longer support it.

How often breakthrough drugs are approved

CDER publishes a list of approvals for drugs with breakthrough designation. On this site's designations tool, which counts originals and supplements, breakthrough approvals by year were:

Year2019202020212022202320242025
Breakthrough approvals25313026173035

CDER's list totals 337 breakthrough approvals from 2013 through 2025, and 15 more in 2026 through June 30, the latest update in the data as of November 2026.

Accelerated approval

Accelerated approval is an approval pathway, not a designation. FDA created it by regulation in 1992 (21 CFR 314 Subpart H for drugs and 21 CFR 601 Subpart E for biologics), and FDASIA wrote it into the statute in 2012. It allows approval based on:

  • A surrogate endpoint, such as tumor shrinkage or a lab marker, that is reasonably likely to predict clinical benefit, or
  • An intermediate clinical endpoint that can be measured earlier than the main outcome, such as death or major illness.

The trade-off is that the sponsor must run confirmatory trials to verify the clinical benefit. If the trials fail or are not carried out with due diligence, FDA can withdraw the approval.

Changes under FDORA (2022)

The Food and Drug Omnibus Reform Act of 2022 (FDORA) tightened the pathway. As described on FDA's accelerated approval program page:

  • FDA can require that confirmatory trials be underway before it grants accelerated approval.
  • Sponsors must report progress on confirmatory trials at regular intervals, which the statute sets at every 180 days.
  • FDA has an expedited procedure to withdraw an approval when confirmatory trials fail to verify benefit or are not conducted with due diligence.

FDA has issued guidance on how it applies these provisions, and that guidance has been updated since 2022, so check the program page for the current version.

On this site's designations tool, CDER's accelerated approval list (350 total approvals as of June 30, 2026) shows: 10 in 2019, 20 in 2020, 17 in 2021, 9 in 2022, 12 in 2023, 11 in 2024, 13 in 2025 and 5 in 2026 through June 30. Many are cancer drugs, where tumor response rates are common surrogate endpoints.

Priority review

Priority review changes only the review clock. Under the user fee agreements known as PDUFA, FDA's goal is to act on a priority application within 6 months, compared with 10 months for a standard review. For new molecular entities and original biologics, the clock starts at the 60-day filing date, so the total from submission is about 8 months for priority and 12 months for standard.

FDA decides whether to grant priority review when it files the application, within 60 days of receipt. The standard is that the drug, if approved, would be a significant improvement in the safety or effectiveness of treating, diagnosing or preventing a serious condition. FDA's priority review page gives examples, such as better effectiveness, fewer serious side effects or improved adherence.

A sponsor can also get priority review by redeeming a priority review voucher, earned under separate programs for certain rare pediatric diseases, tropical diseases and medical countermeasures. Those programs have their own eligibility rules and expiry provisions, which Congress has changed several times.

The target date for FDA's action is the PDUFA date; what is a PDUFA date explains how it is set, and the PDUFA calendar lists upcoming ones.

How the programs combine

The programs are independent. A typical path for an oncology drug could be:

  1. Fast track granted on early data.
  2. Breakthrough therapy granted after striking phase 1 or 2 results.
  3. Rolling submission of the marketing application.
  4. Priority review granted at filing.
  5. Accelerated approval on response rate, with a confirmatory phase 3 trial underway.

Keytruda (pembrolizumab) is an example of a drug that carries every flag the site tracks: novel, breakthrough, accelerated, priority and orphan. Its drug page shows 110 approved uses in Drugs@FDA, counting the original approval and efficacy supplements, as of November 2026.

Among 2026 novel drug approvals matched to Drugs@FDA records, 31 of 48 had priority review, as of November 2026. FDA's breakthrough and accelerated approval lists, which run through June 30, 2026, show 6 breakthrough and 5 accelerated approvals among 2026 novel drugs to that date. For the full year's list, see FDA novel drug approvals in 2026.

  • Regenerative medicine advanced therapy (RMAT): created by the 21st Century Cures Act of 2016 for cell therapies, gene therapies and some tissue products for serious conditions. It offers breakthrough-like benefits and is mostly handled by CBER.
  • Orphan drug designation: not an expedited program, but often combined with one. It brings exclusivity and fee incentives for rare diseases; see orphan drug designation explained.

What the data can and cannot show

FDA publishes which approved drugs used each program, but generally not which drugs in development hold a designation, since that is confidential unless the sponsor discloses it. Companies often announce designations in press releases, which is where most public pipeline lists come from. The counts above also cover CDER only: most vaccines and cell and gene therapies are reviewed by CBER and are not in these lists.

Frequently asked questions

What is the difference between breakthrough therapy and fast track?
Both are designations for drugs that treat serious conditions. Fast track needs data showing potential to address an unmet need, while breakthrough therapy needs preliminary clinical evidence of substantial improvement over available therapy and brings more intensive FDA guidance.
Is accelerated approval the same as priority review?
No. Accelerated approval is a type of approval based on a surrogate or intermediate endpoint and needs confirmatory trials, while priority review only shortens FDA's review goal to 6 months.
Can a drug have more than one expedited program?
Yes. The programs are independent, so one drug can be fast track or breakthrough during development and then receive priority review and accelerated approval.
How long is priority review?
FDA's goal is to act within 6 months, compared with 10 months for standard review. For new molecular entities and original BLAs, the clock starts at the 60-day filing date.

For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.

Keep reading